Slide 1: Annual Report Presentation August 2018
ANNUAL REPORT PRESENTATION AUGUST 2018
Slide 2: Disclaimer
DISCLAIMER This investor presentation (Presentation) has been prepared by Cann Group Limited (ABN 25 603 Investment risk 949 739) (Cann) and comprises written material regarding Cann. An investment in Cann shares is subject to known and unknown risks, some of which are beyond the control of Cann. Ca
Slide 3: Disclaimer
DISCLAIMER Past performance All rights reserved Investors should note that past performance, including any pro forma historical information in this Several photographs contained in this Presentation are the property of Cann and are protected Presentation, is given for illustrative purposes only and
Slide 4: Allan McCallum, Chairman
ALLAN McCALLUM CHAIRMAN GROUP LIMITED
Slide 5: Financial Results
FINANCIAL RESULTS 2018 2017 $ $ Revenue 560,000 - Other income 943,391 8,421 Administration and corporate costs (7,286,394) (1,642,100) Research and development costs (776,430) (647,782) Fair value adjustment of biological assets 104,820 - Changes in inventories of finished goods and work-in-progres
Slide 6: Regulatory Approvals
REGULATORY APPROVALS 6 Cann has established a strong record of meeting or exceeding the standards required in securing regulatory approvals • First Australian recipient of research & medicinal cannabis cultivation licences • Permits granted for two cultivation & R&D facilities currently operational
Slide 7: Strong Research Capability Central to Strategy
STRONG RESEARCH CAPABILITY CENTRAL TO STRATEGY 7 • Large investment in people & resources • Key relationships adding value across areas including genetics, analytics, cultivation & delivery systems • Committed to a science-based growth strategy
Slide 8: Expansion Program Reflects Confidence in Future Opportunities
EXPANSION PROGRAM REFLECTS CONFIDENCE IN FUTURE 8 OPPORTUNITIES • Cann is well progressed in its aggressive expansion plans • Expected growth in demand for safe, innovative medicinal cannabis treatments locally & overseas • Access to treatments expected to improve • Ideally positioned to capitalise
Slide 9: Peter Crock, CEO – Operations Review
9 PETER CROCK CEO Operations review
Slide 10: Successful Production & Expanded Facilities
SUCCESSFUL PRODUCTION & EXPANDED FACILITIES 10 • Harvested first medicinal cannabis at Southern facility in August 2017 • Numerous harvests completed throughout FY2018 • Southern facility – added capacity with new cultivation rooms + new drying & storage rooms • Northern facility – focus on genetics
Slide 11: Stage 3 Expansion Announced
STAGE 3 EXPANSION ANNOUNCED 11 • Heads of agreement signed in June 2018 with Australia Pacific Airports Melbourne (APAM) • APAM proposed to fund & conduct primary build – multi-million dollar contribution • Cann Group to complete fit-out & technology deployment of 37,000m² facility – state-of-the-ar
Slide 12: Positive Progress on Licences & Permits
POSITIVE PROGRESS ON LICENCES & PERMITS 12 • October 2017 – received import/export licence - Provides ability to apply for permit to export raw cannabis material & oil for analytical testing - Working with Aurora Cannabis & Anandia Laboratories to identify suitable genetics & products for import - F
Slide 13: Value-Adding Partnerships
VALUE-ADDING PARTNERSHIPS 1 3 • July 2017 – signed technical services agreement with major Canadian producer & largest shareholder Aurora Cannabis – covers information & support across cultivation, processing, extraction, manufacturing & analysis of medicinal cannabis • June 2018 – MOU signed for ex
Slide 14: Product Development & Patient Access
PRODUCT DEVELOPMENT & PATIENT ACCESS 1 4 • September 2017 – Cann Group partnered with Medicinal Cannabis Medicines Portal to facilitate streamlined medicinal cannabis prescribing & access in Australia • First patients recently approved for treatment with a product via Cann Group – being an oil produ
Slide 15: Corporate Developments
CORPORATE DEVELOPMENTS 1 5 • November 2017 – announced & later completed institutional placement & share purchase plan raising a total of $78m ($2.50 per share) - new funds to support the construction of Cann’s Stage 3 facility - Aurora Cannabis increased its stake from 19.9% to 22.9% as part of the
Slide 16: 2019 Outlook Sees Positive Momentum Continuing
2019 OUTLOOK SEES POSITIVE MOMENTUM CONTINUING 1 6 • Strengthening team & capabilities as Stage 3 facility is developed • Progress development of final dose forms for patients • Pursuit of export permits & commencement of export sales • Streamlining patient access via further engagement with the med
Slide 17: Contacts
CONTACTS Peter Crock INVESTOR / MEDIA RELATIONS CEO Matthew Wright Cann Group Limited NWR Communications Pty Ltd Ph: +61 (0)3 9095 7088 Ph: +61 (0)451 896 420 E: contact@canngrouplimited.com E: matt@nwrcommunications.com.au